Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
Algernon Pharmaceuticals (AGNPF) has received a USPTO notice of allowance for patent application 17/255,364 covering its lead chronic kidney disease (CKD) drug NP-251 (Repirinast). The patent, valid through 2038, covers Repirinast's use alone or combined with telmisartan for treating renal fibrosis or kidney disease.
The company already holds corresponding patents in Japan and China, with pending applications in Europe and Canada. The CKD market is projected to grow from $84.85 billion in 2025 to $109.95 billion by 2030, with a 5.32% CAGR.
Preclinical data showed Repirinast reduced fibrosis by 50.6% at 90 mg/kg dose, outperforming telmisartan (32.6% reduction) and cenicriviroc (31.9% reduction). The combination of Repirinast (30 mg/kg) with telmisartan (3 mg/kg) achieved a 54.2% fibrosis reduction with statistical significance.
Algernon Pharmaceuticals (AGNPF) ha ricevuto un avviso di autorizzazione dell'USPTO per la domanda di brevetto 17/255,364 che copre il suo farmaco principale per la malattia renale cronica (CKD) NP-251 (Repirinast). Il brevetto, valido fino al 2038, riguarda l'uso del Repirinast da solo o in combinazione con telmisartan per il trattamento della fibrosi renale o della malattia renale.
L'azienda detiene già brevetti corrispondenti in Giappone e Cina, con domande pendenti in Europa e Canada. Si prevede che il mercato della CKD cresca da 84,85 miliardi di dollari nel 2025 a 109,95 miliardi di dollari entro il 2030, con un tasso di crescita annuale composto (CAGR) del 5,32%.
I dati preclinici hanno mostrato che il Repirinast ha ridotto la fibrosi del 50,6% a una dose di 90 mg/kg, superando il telmisartan (riduzione del 32,6%) e il cenicriviroc (riduzione del 31,9%). La combinazione di Repirinast (30 mg/kg) con telmisartan (3 mg/kg) ha ottenuto una riduzione della fibrosi del 54,2% con significatività statistica.
Algernon Pharmaceuticals (AGNPF) ha recibido un aviso de concesión de la USPTO para la solicitud de patente 17/255,364 que cubre su medicamento principal para la enfermedad renal crónica (CKD) NP-251 (Repirinast). La patente, válida hasta 2038, abarca el uso de Repirinast solo o combinado con telmisartan para el tratamiento de la fibrosis renal o la enfermedad renal.
La empresa ya posee patentes correspondientes en Japón y China, con solicitudes pendientes en Europa y Canadá. Se proyecta que el mercado de la CKD crezca de 84,85 mil millones de dólares en 2025 a 109,95 mil millones de dólares para 2030, con una tasa de crecimiento anual compuesta (CAGR) del 5,32%.
Los datos preclínicos mostraron que Repirinast redujo la fibrosis en un 50,6% a una dosis de 90 mg/kg, superando a telmisartan (reducción del 32,6%) y cenicriviroc (reducción del 31,9%). La combinación de Repirinast (30 mg/kg) con telmisartan (3 mg/kg) logró una reducción de la fibrosis del 54,2% con significancia estadística.
알저넌 제약 (AGNPF)가 만성 신장 질환(CKD) 치료제 NP-251 (레피리나스트)에 대한 특허 출원 17/255,364의 승인 통지를 미국 특허청(USPTO)으로부터 받았습니다. 이 특허는 2038년까지 유효하며, 레피리나스트의 단독 사용 또는 텔미사르탄과 결합하여 신장 섬유증 또는 신장 질환을 치료하는 용도를 다룹니다.
회사는 일본 및 중국에서 해당 특허를 이미 보유하고 있으며, 유럽 및 캐나다에는 특허 출원이 진행 중입니다. CKD 시장은 2025년 848억 5천만 달러에서 2030년까지 1,099억 5천만 달러로 성장할 것으로 예상되며, 연평균 성장률(CAGR)은 5.32%입니다.
전임상 데이터에 따르면 레피리나스트는 90 mg/kg의 용량에서 섬유증을 50.6% 감소시켜 텔미사르탄(32.6% 감소) 및 세니크리비록(31.9% 감소)을 초과하는 성과를 보였습니다. 레피리나스트(30 mg/kg)와 텔미사르탄(3 mg/kg)의 조합은 통계적으로 유의미한 54.2%의 섬유증 감소를 달성했습니다.
Algernon Pharmaceuticals (AGNPF) a reçu un avis d'approbation de l'USPTO concernant la demande de brevet 17/255,364 couvrant son principal médicament pour la maladie rénale chronique (CKD), le NP-251 (Repirinast). Le brevet, valable jusqu'en 2038, couvre l'utilisation de Repirinast seul ou en combinaison avec le telmisartan pour le traitement de la fibrose rénale ou des maladies rénales.
L'entreprise détient déjà des brevets correspondants au Japon et en Chine, avec des demandes en attente en Europe et au Canada. Le marché de la CKD devrait passer de 84,85 milliards de dollars en 2025 à 109,95 milliards de dollars d'ici 2030, avec un taux de croissance annuel composé (CAGR) de 5,32%.
Les données précliniques ont montré que le Repirinast réduisait la fibrose de 50,6% à une dose de 90 mg/kg, surpassant le telmisartan (réduction de 32,6%) et le cenicriviroc (réduction de 31,9%). La combinaison de Repirinast (30 mg/kg) avec le telmisartan (3 mg/kg) a atteint une réduction de la fibrose de 54,2% avec une signification statistique.
Algernon Pharmaceuticals (AGNPF) hat eine Genehmigungsbenachrichtigung des USPTO für die Patentanmeldung 17/255,364 erhalten, die sich auf sein führendes Medikament zur chronischen Nierenerkrankung (CKD) NP-251 (Repirinast) bezieht. Das Patent, das bis 2038 gültig ist, umfasst die Verwendung von Repirinast allein oder in Kombination mit Telmisartan zur Behandlung von Nierenfibrose oder Nierenerkrankungen.
Das Unternehmen hält bereits entsprechende Patente in Japan und China, mit anhängigen Anträgen in Europa und Kanada. Der CKD-Markt wird voraussichtlich von 84,85 Milliarden Dollar im Jahr 2025 bis auf 109,95 Milliarden Dollar im Jahr 2030 wachsen, mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 5,32%.
Vorklinische Daten zeigten, dass Repirinast die Fibrose bei einer Dosis von 90 mg/kg um 50,6% reduzierte und somit Telmisartan (32,6% Reduktion) und Cenicriviroc (31,9% Reduktion) übertraf. Die Kombination von Repirinast (30 mg/kg) mit Telmisartan (3 mg/kg) erzielte eine statistisch signifikante Reduzierung der Fibrose um 54,2%.
- Secured USPTO patent protection through 2038 for Repirinast in kidney disease treatment
- Demonstrated superior efficacy with 50.6% fibrosis reduction compared to existing treatments
- Already holds patents in Japan and China, with pending applications in Europe and Canada
- Operating in a growing market projected to reach $109.95B by 2030
- None.
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/255,364 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast).
The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has been issued corresponding patents in Japan and China, with applications pending in Europe and Canada.
The Chronic Kidney Disease Market size is estimated at USD 84.85 billion in 2025, and is expected to reach USD 109.95 billion by 2030, at a CAGR of
Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms.
“Algernon’s intellectual property strategy for our innovative drug repurposing programs continues to be very successful,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “It is increasingly more difficult to confirm novelty and receive a method of use patent with the advent of AI being used as a drug discovery tool. It is an important achievement and provides substantial protection for Repirinast and its use as a treatment for kidney disease.”
Preclinical Data
Data from the UUO study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis as measured by Sirius Red staining over untreated controls:
- Telmisartan (3 mg/kg), a positive control, reduced fibrosis by
32.6% (p<0.001) - Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced fibrosis by
31.9% (p=0.00032). - Repirinast (90 mg/kg) reduced fibrosis by
50.6% (p<0.000001). - Repirinast (30 mg/kg) reduced fibrosis by
20.8% (p>0.05). - The combination of Repirinast (30 mg/kg) and telmisartan (3 mg/kg) reduced fibrosis by
54.2% (p<0.000001). In addition, the mass of the fibrotic kidney was lower than the negative control (p<0.001).
About NP-251 (Repirinast)
Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of Asthma. Romet™ was marketed for over 25 years in Japan. Mitsubishi discontinued manufacturing and sales of the drug in 2013. Accordingly, Algernon has retained Zhejiang Ausun Pharmaceutical in Zhejiang, China to manufacture a cGMP Repirinast supply.
Mast cells are recruited to sites of cellular damage, and degranulation of mast cells leads to release of a myriad of proinflammatory chemical mediators which lead to tissue damage in a self-propagating cascade. NP-251 binds to receptors on mast cells and prevents their degranulation, which the Company believes could help prevent fibrosis in multiple organ classes including the kidneys.
About Algernon Pharmaceuticals
Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
1 https://www.mordorintelligence.com/industry-reports/chronic-kidney-disease-market
FAQ
What efficacy did Repirinast (AGNPF) show in kidney fibrosis reduction compared to other treatments?
How long will Algernon's (AGNPF) new USPTO patent protection for Repirinast last?
What is the market size projection for Chronic Kidney Disease treatment where AGNPF's Repirinast will compete?
What were the results of combining Repirinast with telmisartan in AGNPF's kidney disease studies?
In which countries does AGNPF currently hold patents for Repirinast in kidney disease treatment?
